

ARTHUR, M. et al.
Appl. No. 10/650,074
January 13, 2006

Applicants note the Examiner's comments on page 3 of the Office Action indicating that, upon allowance of linking claims, the restriction require as to the linked inventions will be withdrawn.

Finally, Applicants confirm that claim 20 should be classified with Group I, as is evident from page 64, line 17 of the application which indicates Spiperone is a 5HT₂ receptor antagonist.

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100